Clinical Trial Update: A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating ARN-509 (apalutamide) in combination with abiraterone acetate in participants with metastatic castration-resistant prostate ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• JNJ-56021927 (ARN-509) (apalutamide)

Snippet

Sponsor: Aragon Pharmaceuticals, Inc. | Conditions: Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING